@article{31045c055dac4a7f893218dc29b5f8f1,
title = "Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up",
abstract = "ESMO Guidelines for Mantle Cell Lymphoma",
author = "{The ESMO Guidelines Working Group} and M. Dreyling and C. Geisler and O. Hermine and Kluin-Nelemans, {H. C.} and {Le Gouill}, S. and S. Rule and O. Shpilberg and J. Walewski and M. Ladetto",
note = "Funding Information: MD has reported scientific advisory boards for Bayer, Celgene, Gilead, Janssen and Pfizer; support of academic trials for Celgene, Janssen, Mundipharma, Pfizer and Roche; speaker{\textquoteright}s honoraria: Celgene, Janssen, Mundipharma, Pfizer and Roche. CG has reported scientific advisory boards for Roche, Celgene, Janssen and GlaxoSmithKline; support of academic trials by Celgene and Janssen. SR: advisory boards for Johnson & Johnson, Pharmacyclics, Roche, Napp and Celgene. OS: advisory boards for Roche and Takeda; research grants from Roche and Janssen. JW: advisory boards for Celgene, Roche, Mundipharma, Takeda, Bayer, Boehringer Ingelheim, Janssen and Amgen; research grants from Roche, Celgene, GlaxoSmithKline and Mundipharma; speaker{\textquoteright}s honoraria for Roche, Mundipharma, Celgene and Takeda. ML has reported speaker{\textquoteright}s bureau for Celgene, Janssen-Cilag, Roche, Bayer, Amgen and Mundipharma; research contracts from Celgene, Pfizer, Mundipharma and Roche; funds received from Amgen, Roche and Italfarmaco. SL, OH and HK have reported no potential conflicts of interest.",
year = "2014",
month = sep,
day = "1",
doi = "10.1093/annonc/mdu264",
language = "English",
volume = "25",
pages = "iii83--iii92",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Ltd.",
}